Experienced and dedicated team
- comprehensive set of proven track records
- always meeting or exceeding KPI
World-class advisory board
- includes Nobel prize laureate and world leading professors
- business experts and serial entrepreneurs with exits over $1B
- GR experts
- completed phase I/IIa clinical trial
- initiated non-US phase II clinical trial
Unique mechanism of action of the lead product
- changes tumor microenvironment
- reduces chronic inflammation
- enhances therapeutic benefits of other treatment modalities
Comprehensive international IP protection
High anticipated ROI and short time to exit
